Antibody Drug Conjugates: Redefining Precision Oncology
By Dhruv Chachad, Ph.D, Postdoctoral Fellow, MD Anderson Cancer Center
Cancer treatment has long faced a fundamental trade-off – therapies powerful enough to kill tumors often come at the cost of damaging healthy tissue. Antibody drug conjugates (ADCs) are beginning to change that equation. By combining the targeting precision of biologics with the potency of chemotherapy, ADCs are emerging as one of the most impactful innovations in oncology today.
At a high level, ADCs function like guided therapies. An antibody is designed to identify a particular marker on cancer cells, and it carries a powerful payload that is delivered once inside the cell via a customized linker. The result is a more selective form of treatment – one that aims to concentrate toxicity where it is needed while limiting exposure elsewhere. While the concept may sound modern, it traces back over a century to Paul Ehrlich’s idea of a “magic bullet”. What has changed in recent years is the technology needed to make that vision practical.
Early attempts at ADCs struggled with instability and limited efficacy. Today, advances in antibody engineering, linker chemistry, and payload design have transformed ADCs into a clinically validated and commercially successful class of therapeutics. Over the past decade, they have moved from experimental therapies to a central part of cancer treatment strategies.
Even with these challenges, the direction of the field is clear. ADCs are no longer a niche innovation. They are rapidly becoming a foundational innovation in oncology.
Several ADCs now stand out not only for their clinical performance but also for their commercial impact. Enhertu has become a defining example of the field’s evolution. Originally developed through a combined effort by AstraZeneca and Daiichi Sankyo for HER2-positive breast cancer, it has expanded into what is now termed “HER2-low” disease, effectively broadening the addressable patient population. This shift has had major implications, redefining how oncologists think about target expression and eligibility for targeted therapies. This ADC alone has brought in around $3.75B in revenue in 2024. The groundwork for this class was laid by a previous HER2-directed ADC, Roche’s Kadcyla, which showed that tailored chemotherapeutic administration could enhance outcomes in patients with residual disease following initial treatment. Together, these two therapies illustrate how iterative improvements in ADC design – particularly linker stability and payload potency – can translate into meaningful gains for patients.
ADCs are also reshaping treatment landscapes in other difficult-to-treat malignancies. Trodelvy, by Gilead Sciences, has expanded options for patients with triple-negative breast cancer, a subtype historically associated with limited targeted therapies. This drug brings in around $1.35B in revenue annually. Padcev, product of a collaboration between Astellas Pharma and Pfizer, has similarly changed the standard of care in advanced urothelial cancer, particularly when combined with immunotherapy. Meanwhile, Adcetris, from Pfizer/Takeda, remains a therapeutic and commercial cornerstone in certain lymphomas, underscoring the versatility of ADCs across both solid tumors and hematologic malignancies.
What unites these therapies is not just their mechanism but their ability to address previously unmet clinical needs while also achieving significant commercial success. For industry stakeholders, this dual impact has positioned ADCs as one of the fastest-growing segments in oncology drug development.
As the field matures, attention is shifting toward the next generation of ADC technologies. One promising direction is the development of bispecific ADCs. These are molecules designed to recognize two different targets on the tumor instead of one. This approach aims to address a persistent challenge in cancer treatment: tumor heterogeneity. By engaging multiple targets simultaneously, bispecific ADCs may improve tumor selectivity and reduce the likelihood of resistance. While these agents are still largely in clinical development, early results suggest they could further expand the reach of this therapeutic platform.
Looking ahead, several trends are likely to define the trajectory of ADCs over the next three to five years. First, ADCs are moving earlier in the treatment paradigm. Instead of being reserved for late-stage disease, they are increasingly being tested in earlier lines of therapy, including settings where the goal is cure rather than controlling the disease. Second, the definition of targetable patient populations is expanding. The success of HER2-low therapies has demonstrated that even modest levels of target expression can be clinically meaningful, opening the door to a much broader range of indications.
Combination strategies are also expected to play a critical role. ADCs are being paired with immunotherapies, targeted agents, and other modalities to enhance efficacy and overcome resistance. At the same time, innovation in payload design – such as immune-modulating or non-traditional cytotoxic agents – may further differentiate next-generation ADCs from their predecessors.
Despite this progress, challenges remain. As the use of ADCs grows, controlling toxicity especially off-target effects and organ-specific risks, will be crucial. Equally important will be understanding mechanisms of resistance, including changes in antigen expression and intracellular processing, which can limit long-term efficacy.
Even with these challenges, the direction of the field is clear. ADCs are no longer a niche innovation. They are rapidly becoming a foundational innovation in oncology. For clinicians, they offer new ways to treat patients who previously had limited options. For the industry, they represent a scalable platform with significant commercial and scientific potential. In many ways, the promise of ADCs reflects a shift in therapeutic options, moving from broadly applied therapies toward more precise, targeted interventions. If current trends continue, the next few years will not only expand the reach of ADCs but may also redefine how cancer itself is treated.